Key facts
- This page summarizes Stephen T. Worland's Form 4 filing for eFFECTOR Therapeutics, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 17 May 2024, 16:00.
Stephen T. Worland - 15 May 2024 Form 4 Insider Report for eFFECTOR Therapeutics, Inc.
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- N/A
- Reported as of
- 15 May 2024
- Net transaction value
- +$3,039
- SEC form
- 4
- Accepted by SEC
- 17 May 2024, 16:00:15 UTC
- Prior SEC filing
- 21 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Byrnes, Attorney-in-Fact for Stephen T. Worland
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Stephen T. Worland filed Form 4 for eFFECTOR Therapeutics, Inc. on 17 May 2024.
Change
- Previous filing in this sequence was filed on 21 Feb 2024.
- Current net transaction value: +$3,039.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EFTR
transaction
Common Stock
Award
- Transaction value
- $3,039
- Shares
- +1,806
- Change %
- +17%
- Price
- $1.68
- Shares after
- 12,494
- Date
- 15 May 2024
- Ownership
- Direct
- Footnotes
- F1
EFTR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 22,493
- Date
- 15 May 2024
- Ownership
- By trust
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
These shares were acquired under the eFFECTOR Therapeutics, Inc. 2021 Employee Stock Purchase Plan.